Business Context and Reporting Period
Company: Tivic Health Systems, Inc. (TIVC)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Tivic Health is a diversified therapeutics company focused on bioelectronic medicine and immunotherapeutics. Its primary commercial product is ClearUP, an FDA-approved over-the-counter device for sinus pain and congestion. The company is developing a non-invasive cervical vagus nerve stimulation (ncVNS) platform and, in February 2025, acquired exclusive license rights to Entolimod, a late-stage TLR5 agonist for acute radiation syndrome (ARS).
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0.78 million | $1.18 million |
| Cost of Sales | $0.78 million | $0.89 million |
| Gross Profit | $0.002 million | $0.29 million |
| Operating Expenses | $5.66 million | $8.53 million |
| Net Loss | $(5.66) million | $(8.24) million |
| Cash Used in Operating Activities | $(5.73) million | $(8.51) million |
| Cash and Cash Equivalents (End of Period) | $2.00 million | $3.40 million |
| Working Capital | $2.37 million | $3.25 million |
| Accumulated Deficit | $(43.54) million | $(37.89) million |
Note: Gross margin was negligible in 2024 due to significant inventory reserves.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 34% to $0.78 million, driven by a 41% drop in unit sales (approx. 4,400 units in 2024 vs. 7,400 in 2023). This was primarily due to reduced marketing spend.
- Gross Profit Compression: Gross profit collapsed to $2,000 from $287,000. This was caused by a $354,000 inventory reserve for obsolete raw materials and $21,000 in disposal costs associated with changing logistics providers.
- Expense Reduction: Total operating expenses decreased 34% to $5.66 million. Savings were achieved through reduced headcount, lower advertising spend ($332k reduction), and decreased consulting fees.
- Supply Chain Restructuring: The company terminated its fulfillment agreement with ALOM Technologies in August 2024 to reduce costs, moving to in-house assembly and third-party logistics.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Management has raised substantial doubt about the company's ability to continue as a going concern. With cash of $2.0 million and a burn rate of approximately $5.7 million annually, resources may be insufficient to meet anticipated needs for the next 12 months without additional financing.
Recent Strategic Developments (Post-Period)
- Statera Acquisition: In February 2025, Tivic acquired exclusive worldwide license rights to Entolimod (TLR5 agonist) for ARS treatment. Consideration included $300,000 cash and $1.2 million in stock. Future milestone payments could total up to $8.25 million depending on development success.
- Equity Line of Credit: In March 2025, the company entered an agreement with Mast Hill Fund to sell up to $25 million of common stock over 24 months.
- Reverse Stock Split: A 1-for-17 reverse stock split was implemented on March 7, 2025, to regain compliance with Nasdaq listing requirements after the stock price fell below $1.00 for 33 consecutive days.
Key Risks
- Liquidity: Dependence on equity financing which may result in significant dilution.
- Internal Controls: A material weakness in internal control over financial reporting was identified due to small staffing levels in the accounting team.
- Regulatory: Reliance on the FDA "Animal Rule" for Entolimod approval; no guarantee of approval or timeline.
- Supply Chain: Significant reliance on third-party manufacturers in China for electronic components.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.0 million cash balance against the $5.7 million annual burn rate and the timeline for closing the $25 million equity line of credit.
- Inventory Valuation: Review the $338,000 inventory reserve and the rationale for the obsolescence write-downs impacting 2024 gross margins.
- Statera Milestones: Assess the financial impact of the $1.75 million in immediate development milestones and potential future royalties associated with the Entolimod license.
- Nasdaq Compliance: Confirm the company's continued compliance with Nasdaq listing standards following the March 2025 reverse stock split.
- Internal Controls: Monitor management's remediation plan for the identified material weakness in financial reporting controls.